ANAPLASMOSIS AND BABESIOSIS OF CATTLE IN CENTRAL REGION OF RUSSIAN FEDERATION

An epizootological monitoring of anaplasmosis and babesiosis of cattle of Aberdeen-Angus breed in the Bryansk region was carried out. Acarological and entomological studies made it possible to detect Dermacentor reticulatus ixodic ticks on animals in spring, and Tabanus bovinus, T. sudeticus, Chrysops spp., Haematopota spp. and blood-sucking zoophilic flies Stomoxys calcitrans, Haematobia spp. summer and early spring. The higher number of gadflies and bloodsucking flies (mechanical carriers of Anaplasma marginale), compared with ixodic ticks (Babesia divergens biological carriers) in a number of areas of the Bryansk region, explains the widespread anaplasmosis and high rates of parasitemia. The acute course of anaplasmosis and babesiosis in a mixed form is characterized by persistent fever, decreased or no appetite, ataxia, tachycardia, shortness of breath, mucous membrane anemia. According to the results of research, the maximum intensity of the epizootic process in anaplasmosis and babesiosis was found in the Trubchevskiy district of the Bryansk region, which is caused by the numerous biotopes of Ixodic ticks Dermacentor reticulatus.In the clinically expressed form of anaplasmosis and babesiosis, 1% oxytetracycline (LA 200) and Babezan 12% intramuscularly were administered to animals once. For the prevention of diseases in young stock, taking into account the absence of non-sterile immunity, during the period of activity of ixodic ticks and blood-sucking dipter, the above preparations were prescribed three times: in spring (March-April), in summer (late June-July) with high rainfall and in autumn (September-October).In cases of severe anaplasmosis and babesiosis Oxytetracycline 1% (LA 200) and Babesan, 12% are prescribed simultaneously in the mixed form with the means of pathogenetic and symptomatic therapy. With moderate and severe babesiosis accompanied by fever, depression, and lack of appetite, Babezan 12% is used fractionally, i.e. 50% of the therapeutic dose on the day of manifestation of the first clinical signs and the rest in 18–20 hours.